Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2018, Article ID 4673061, 7 pages
Research Article

Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease’s Statin Therapy in Men

1Department of Physiology, Faculty of Natural Sciences and Mathematics, “Ss. Cyril and Methodius” University, Skopje, Macedonia
2Department of Abdominal Surgery, Faculty of Medicine, “Ss. Cyril and Methodius” University, Skopje, Macedonia
3Department of Radiology and Physical Therapy and Department of Internal Diseases in Ruminants, Faculty of Veterinary Medicine, “Ss. Cyril and Methodius” University, Skopje, Macedonia

Correspondence should be addressed to Nikola Hadzi-Petrushev; km.miku.fmp@alokin

Received 22 January 2018; Accepted 18 April 2018; Published 17 May 2018

Academic Editor: Robert Gogal

Copyright © 2018 Nikola Hadzi-Petrushev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Oxidative stress and inflammation contribute to the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD), and the control of lipid status by statins may help to stop the progression of NAFLD. We hypothesized that the addition of antioxidant vitamins C and E to atorvastatin therapy is associated with improved serum enzyme antioxidant status. NAFLD-related serum parameters and the activity of antioxidant enzymes, before and after 3 months of treatment, were determined in patients receiving atorvastatin alone or atorvastatin plus antioxidants. Compared to healthy controls, the patients, before receiving therapy, had increased catalase and glutathione reductase, with no significant difference in glutathione peroxidase activity. After the treatment, the levels of all three antioxidant markers were reduced to the same degree in both groups of patients, indicating therapy-induced lower level of reactive oxygen species production and/or improved nonenzymatic antioxidant mechanisms. Both therapies led to the normalization of the serum lipid profile and aminotransferase levels in the patients, but the reduction in CRP, although significant, did not reduce levels to those of the controls. The obtained results favor the notion that therapy with atorvastatin alone is equally efficient during the early stages of NAFLD, regardless of the addition of antioxidant vitamins. This trial is registered with TCTR20180425001.